PTD-DBM vs Pentapeptide-18
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Leuphasyl, Tyr-Ala-Gly-Phe-Leu
Pentapeptide-18 is Lipotec's Leuphasyl, a 'Botox-like' cosmetic peptide modeled on enkephalins, the body's own calming neuropeptides. It is mostly sold alongside Argireline, with the claim that the two relax expression lines better together. It is a cosmetic ingredient, and the evidence is small and mostly manufacturer-run.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Pentapeptide-18 (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | Pentapeptide-18 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | Pentapeptide-18 is Tyr-Ala-Gly-Phe-Leu, a close copy of Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) with one amino acid swapped. The theory is that it binds enkephalin receptors on nerve endings, which dampens nerve activity and lowers acetylcholine release at the junction with facial muscles. Argireline works at a different step (the SNARE complex inside the nerve ending), which is why the two get marketed as a combo. The same big caveat as Argireline applies: it is sold on a nerve-to-muscle mechanism, but nobody has shown in living skin that a topical cream delivers enough peptide to the muscle to do this. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | About 2-5% of the commercial solution in a finished product Once or twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (serums, creams) |
| Typical Duration | Applied over several weeks in animal studies | 28 days to 2 months in studies; ongoing use to maintain any effect |
| Best Time to Take | Not established (topical in animal studies) | Morning and/or evening, on clean skin |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | The most quoted numbers come from a Lipotec study: about 11% wrinkle reduction with 5% Leuphasyl alone over 28 days in a small panel, and about 25% with 5% Leuphasyl plus 5% Argireline. The company calls that synergy, but on its own figures the combination roughly equals the two effects added together, so 'synergistic' is a stretch. The one journal paper we found is Dragomirescu and colleagues (2014, Cosmetics, MDPI), which tested 0.5%, 1% and 2% emulsions around the eyebrows and eyes for efficacy and safety. Trade summaries say only the 2% cream gave a significant improvement after two months in about 20 volunteers; we could not read the full paper to confirm the numbers. A 2020 review of cosmetic peptides lists it among the neurotransmitter-inhibitor peptides and notes that much of the support comes from the manufacturer. Bottom line: safe enough as a skincare ingredient and plausible on paper, but expect subtle softening at most, not anything close to an injection. |
Frequently Asked Questions: PTD-DBM vs Pentapeptide-18
What is the difference between PTD-DBM and Pentapeptide-18?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. Pentapeptide-18 is a skin & hair peptide that pentapeptide-18 is lipotec's leuphasyl, a 'botox-like' cosmetic peptide modeled on enkephalins, the body's own calming neuropeptides. it is mostly sold alongside argireline, with the claim that the two relax expression lines better together. it is a cosmetic ingredient, and the evidence is small and mostly manufacturer-run. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or Pentapeptide-18?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while Pentapeptide-18 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and Pentapeptide-18 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and Pentapeptide-18 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.